CN101703824A - 纳米硒、锗元素中药脑猝中痴呆病防治帽 - Google Patents
纳米硒、锗元素中药脑猝中痴呆病防治帽 Download PDFInfo
- Publication number
- CN101703824A CN101703824A CN200910233888A CN200910233888A CN101703824A CN 101703824 A CN101703824 A CN 101703824A CN 200910233888 A CN200910233888 A CN 200910233888A CN 200910233888 A CN200910233888 A CN 200910233888A CN 101703824 A CN101703824 A CN 101703824A
- Authority
- CN
- China
- Prior art keywords
- radix
- accounts
- respectively account
- rhizoma
- account
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 239000011669 selenium Substances 0.000 title claims abstract description 22
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 229910052711 selenium Inorganic materials 0.000 title claims abstract description 20
- 229910052732 germanium Inorganic materials 0.000 title claims abstract description 10
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 title claims abstract description 10
- 230000002265 prevention Effects 0.000 title abstract description 3
- 241001494246 Daphnia magna Species 0.000 title abstract 3
- 239000000835 fiber Substances 0.000 claims abstract description 19
- 239000004744 fabric Substances 0.000 claims abstract description 17
- 239000011032 tourmaline Substances 0.000 claims abstract description 12
- 229910052613 tourmaline Inorganic materials 0.000 claims abstract description 12
- 229940070527 tourmaline Drugs 0.000 claims abstract description 12
- 230000006870 function Effects 0.000 claims abstract description 9
- 238000005516 engineering process Methods 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 239000004575 stone Substances 0.000 claims abstract description 6
- 229920000297 Rayon Polymers 0.000 claims abstract description 4
- 229920006052 Chinlon® Polymers 0.000 claims abstract description 3
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims abstract description 3
- 210000004556 brain Anatomy 0.000 claims description 32
- 230000000694 effects Effects 0.000 claims description 20
- 206010012289 Dementia Diseases 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 11
- 239000011573 trace mineral Substances 0.000 claims description 11
- 235000013619 trace mineral Nutrition 0.000 claims description 11
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 10
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 9
- 241000628997 Flos Species 0.000 claims description 9
- 208000006011 Stroke Diseases 0.000 claims description 9
- 210000000582 semen Anatomy 0.000 claims description 9
- 239000011858 nanopowder Substances 0.000 claims description 7
- 241000237903 Hirudo Species 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 6
- 206010019468 Hemiplegia Diseases 0.000 claims description 5
- 229910010413 TiO 2 Inorganic materials 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 241001116389 Aloe Species 0.000 claims description 4
- 241000489492 Arisaema Species 0.000 claims description 4
- 241000005787 Cistanche Species 0.000 claims description 4
- 241001550206 Colla Species 0.000 claims description 4
- 239000009636 Huang Qi Substances 0.000 claims description 4
- 229910004298 SiO 2 Inorganic materials 0.000 claims description 4
- 241000244155 Taenia Species 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 235000011399 aloe vera Nutrition 0.000 claims description 4
- 210000000941 bile Anatomy 0.000 claims description 4
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 4
- 229910044991 metal oxide Inorganic materials 0.000 claims description 4
- 150000004706 metal oxides Chemical class 0.000 claims description 4
- 241000255791 Bombyx Species 0.000 claims description 3
- 229920000742 Cotton Polymers 0.000 claims description 3
- 241000237636 Pheretima Species 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 claims description 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 241000208340 Araliaceae Species 0.000 claims description 2
- 241000675108 Citrus tangerina Species 0.000 claims description 2
- 241000903946 Clematidis Species 0.000 claims description 2
- 241000209020 Cornus Species 0.000 claims description 2
- 206010013952 Dysphonia Diseases 0.000 claims description 2
- 241000283956 Manis Species 0.000 claims description 2
- 241000217407 Margaritifera Species 0.000 claims description 2
- 239000004677 Nylon Substances 0.000 claims description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 2
- 241000522620 Scorpio Species 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 235000008434 ginseng Nutrition 0.000 claims description 2
- 239000010271 massa medicata fermentata Substances 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 239000002159 nanocrystal Substances 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- 210000002826 placenta Anatomy 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000009490 scorpio Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 210000001835 viscera Anatomy 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N zinc oxide Inorganic materials [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 abstract description 11
- 150000001450 anions Chemical class 0.000 abstract description 9
- 239000004753 textile Substances 0.000 abstract description 5
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 abstract 2
- 229920002972 Acrylic fiber Polymers 0.000 abstract 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 abstract 1
- 230000002155 anti-virotic effect Effects 0.000 abstract 1
- 229910052593 corundum Inorganic materials 0.000 abstract 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 abstract 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 229910001845 yogo sapphire Inorganic materials 0.000 abstract 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 25
- 239000011701 zinc Substances 0.000 description 12
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 11
- 229910052725 zinc Inorganic materials 0.000 description 11
- 208000024827 Alzheimer disease Diseases 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 239000011651 chromium Substances 0.000 description 7
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 6
- 230000002490 cerebral effect Effects 0.000 description 6
- 229910052804 chromium Inorganic materials 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000919 ceramic Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000015654 memory Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000011787 zinc oxide Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 206010036631 Presenile dementia Diseases 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- 206010048259 Zinc deficiency Diseases 0.000 description 3
- 210000004227 basal ganglia Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- -1 polypropylene Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 208000031091 Amnestic disease Diseases 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 244000132059 Carica parviflora Species 0.000 description 2
- 235000014653 Carica parviflora Nutrition 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 2
- 108010076181 Proinsulin Proteins 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 206010041308 Soliloquy Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 201000007201 aphasia Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 238000005868 electrolysis reaction Methods 0.000 description 2
- 238000010035 extrusion spinning Methods 0.000 description 2
- 230000036449 good health Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000002122 magnetic nanoparticle Substances 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000011022 opal Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Chemical compound [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 229910052712 strontium Inorganic materials 0.000 description 2
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 201000003695 Alexia Diseases 0.000 description 1
- 241000752021 Alexia Species 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000003670 Carboxypeptidase B Human genes 0.000 description 1
- 108090000087 Carboxypeptidase B Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 240000001829 Catharanthus roseus Species 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 208000007102 Chronic Brain Damage Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014128 Echopraxia Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000002403 Encephalocele Diseases 0.000 description 1
- 208000001308 Fasciculation Diseases 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229920000914 Metallic fiber Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028293 Muscle contractions involuntary Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 208000019229 Spleen disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010065954 Stubbornness Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000030451 Vascular dementia disease Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000013677 cerebrovascular dementia Diseases 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005421 electrostatic potential Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- VASIZKWUTCETSD-UHFFFAOYSA-N manganese(II) oxide Inorganic materials [Mn]=O VASIZKWUTCETSD-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- SOQBVABWOPYFQZ-UHFFFAOYSA-N oxygen(2-);titanium(4+) Chemical compound [O-2].[O-2].[Ti+4] SOQBVABWOPYFQZ-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000027140 splenic disease Diseases 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004855 vascular circulation Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 229940091251 zinc supplement Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及纳米硒、锗元素中药脑猝中痴呆病防治帽。它属于纺织健康织物帽制品生产技术领域:纳米硒、锗及具有远红外辐射物,同时又具有电磁波屏蔽作用及抗菌抗病毒作用的纳米TiO2、ZnO、Fe2O3、Al2O3等和择放多种微量元素的麦饭石纤维能产生空气中负离子的电气石和中药方剂。用现代纳米技术将上述混合物添加到晴纶或丙烯锦纶的纤维及粘胶纤维织物中制成,用于脑猝中痴呆病防治帽。
Description
技术领域:
本发明涉及纳米硒、锗元素中药脑猝中痴呆病防治帽,属于纺织健康织物帽制品生产技术领域。
背景技术:
根据动物实验和临床大量实践、观察研究微量元素Zn(锌)、Cu(铜)、Fe(铁)、Mn(锰)、Se(硒)、Cr(铬)等与脑血管疾病的发展和预后有较密切的关系,锌在胰岛素中起稳定结构作用,在胰岛素原降解为胰岛素时,需要胰蛋白酶和羧肽酶B的催化,而羧肽酶需锌激活,因而体内缺锌时胰岛素原转变成胰岛素的量减少,血糖升高。所以经临床反复检测证明,糖尿病患者血锌含量明显下降。糖尿病又是脑血管病的主要危险因素之一。故低锌人群是脑猝中的高危人群,所以补锌是关键。
缺锌Zn可使细胞正常代谢受到破坏,使新生的自由基增多,并使细胞易遭受自由基的损害,硒(Se)、锗(Ge)具有强烈清除体内自由基,保护肌体免受氧化物的损伤。脑血管病(包括急性脑出血、蛛网膜下腔出血和脑梗死、脑血管性痴呆症与阿尔漠海默病,即通常所说的老年性痴呆或早老性痴呆)的血浆、红细胞、脑髓液及头发检测中,脑出血组、硒、钒、铬、钙、镁低于正常人。脑出血、脑血栓各元素含量差距无意义。而分析显示钒、铬、铬、钙为脑血管病的保护性元素,而钠为危险性元素。痴呆病发栓中,钡、锶、钙、镁、钴、铬、铜、镍、钛、锰、锌含量低,硒、锗这两种人体重要的生命元素未见报告,磷含量显著增高。
脑血管疾病以脑动脉系统疾病最常见,好发生于40岁以上的中老年人,是危害人类健康、威胁生命、影响劳动力的一种常见、多发病。也系一种脑内血液循环障碍发生而引起。其原因:①血管硬化所引起的占70%,其他如糖尿病脉管炎、先天性脑血管异常、结缔组织病和颅脑外伤等;②血液动力学改变,高血压为常见。其他如低血压、心功能不全、心律失常、脑动脉痉挛和精神紧张、情绪激动、用力过猛;③血液成分改变,如血液粘稠度增高,血脂、血纤维蛋白原增高及凝血机制的异常等。④血管外因素影响,如颈椎病和颅外形成的栓子等,其中动脉硬化是脑猝中的主要危险因素。脑猝中统一病名为中风病(内中风),又分为中络、中经、中腑、中脏。
中络:偏身或一侧手足麻木,或兼有一侧肢体力弱或兼有口舌歪斜者。
中腑:以半身不遂、口舌歪斜、舌强言寡或不语,偏身麻木、神智恍惚或迷蒙为主症者。
中脏:必有神昏或昏愦、半身不遂、口舌歪斜、舌强言寡或不语。
痴呆综合症(dementia syndrome)是一种慢性全面性的精神功能紊乱,以缓慢出现的智能减退为主要临床特征。包括记忆、思维、理解、判断、计算等功能的减退和不同程度的人格改变,而没有意识障碍。多见于起病缓慢、病程较长的脑器质性疾病,故又称慢性脑病综合症(chronic brain syndrome),或称遗忘综合症(amnesia syndrome),也有老年性痴呆和早老性痴呆,是一种发生在老年期和老年前期的以进行性痴呆为主要表现的大脑器质性病变.病变发生在60岁以前的习惯上称早老性痴呆.60岁以后发病者为老年性痴呆.它是一种有选择性和局限性认知功能障碍,主要表现为近事记忆时间、空间、定向、障碍,而无全面性能减退,仅包括记忆解决日常生活的能力,已学到的技能、社交技巧、情绪控制及反应的能力受碍.它的主要病变部位在下丘脑后部及中线附近组织(间脑——颞叶结构),少数可见两侧海马.
本病的病因尚不清楚,部分病例有家族史异常染色体隐性遗传,其他如免疫学因素、慢性病毒感染、微量元素铝在体内超标、沉积中毒有一定的关联。铝的鏊合作用强,可以置换体内的锌,引起脑部组织神经元纤维缠结,而影响其功能。这些痴呆的病人脑部的额、颞、海马、基底节区锌含量低。锌缺乏时谷氨酸类递质效应降低,引起谷氨酸神经元活性下降,从而引起铝能活动下降。另一方面,锌低时Cu-Zn超氧化物歧化酶活性下降,影响自由基的清除功能,使脂褐素、老年斑形成增多。导致脑组织的老化加速,进而出现痴呆。
硒、锗是人体中普遍缺乏的地球水质动植物中又很难得到补充的两种重要生命元素,硒的缺乏清除脑组织自由基能力出现障碍,使自由基大部分积蓄在脑中,加速脂褐素的形成,可影响正常神经元的形态和功能,从而产生老年智能衰退。
铁在脑内的分布以苍白球、壳核、黑质最为丰富。含铁酶系参与能量代谢,氧化磷酸化、神经递质的代谢平衡。铁和铁蛋白有防止脂质过氧化及神经损害的作用。有研究发现,老年斑周围神经细胞含有大量的铁,这些铁可能与β淀粉样前质蛋白基因作用。使细胞产生大量的β淀粉样前质蛋白。因此有人提出,铁的积累是老年痴呆病发病因素之一,这类病人钙吸收低,血清钙也降低,总之老年痴呆病是属于心脑血管同一病因范畴的疾病。主因是患者体内元素失衡,诸如镁、钙、钴、铬、铜、镍、锶、锰、锌等必要的宏微量元素缺乏或低下,引起脂质、糖类、色素等代谢紊乱导致血管疾病、缺血、缺氧所造成。其早期以记忆力障碍为主要自发症状。尤为近期记忆力障碍更为突出,对刚说过的话、做过的事一转身很快就忘了,对中期除近期记忆力继续减退外,智能减退、判断力、理解力下降、定向力障碍、语言了,对中期除近期记忆力继续减退外,智能减退、判断力、理解力下降、定向力障碍、语言单调、固执、多疑、自私、易激动、喃喃自语、人格和行为改变。如行为退缩、无情淡漠、无主动性、缺乏注意力,也可失语、失认、失读、失写等,刻板动作、肌张力增高、掘强反射、模仿动作及厌食、贪食、活动减少、日常生活需人照顾。到了晚期智能完全衰退,生活完全不能自理,呈现完全性缄默。四肢僵硬及锥体束化,大小便失禁,最后多私欲衰竭和继发性感染。
发明内容:
有效地控制高血压病是预防脑猝中的一种中心环节。脑猝中的治疗中医有丰富的传统治疗经验及大量的现代研究,西医治疗有较大的优势,尤其是对重症病例:①急性出血期用脱水降颅压,是本期治疗的关键,控制高颅压脑水肿、防止脑疝及脑保护治疗,恢复期主要改善脑代谢,促进神经功能恢复,对有一定条件的医院患者病况尚好时可考虑外科手术治疗;②缺血性中风急性期除抗脑水肿、脑颅压、脑保护措施同样重要外,与出血性中风有不同之处:有溶栓、抗凝、改善微循环、增加脑供血供氧等措施。
对于痴呆病的防治目前国内外均缺乏行之有效的科学治疗方法和手段,中医治疗虽有传统的治疗方法和现代研究,但疗效有待进一步评价.采取中西医结合治疗和中西的辨证施治对改善某方面的症状,缓减病情发展,控制并发症会有一定帮助.但还是不能最终解决问题.微量元素医学的应用,以全面调节补充人体内元素平衡、提高人体健康体质,补充和拮抗因痴呆症而引起的体内铝高,而钙、锌、硒等元素缺乏的不良体质有一定的治疗效果.
中医药学作为中华民族的传统瑰宝,有数千年的历史。随着微量元素医学的显现,自然界中天然的药物需求量的要求不断增加,传统的中药医学也成为优势突出,最具潜力的经济增长领域,发展前景十分广阔。所以中药现代化的研究必须要在继承传统的中医药学的基础上充分利用现代最先进的前沿科学技术手段中药纳米技术与人体元素平衡科学和现代健康纺织织物的有机结合,以不断创新的思路使中医药学科学地运用到日常生活中,达到“健康、有效、安全、可控”,使中医药学在防治脑血管疾病及痴呆病方面,为人类健康事业,尤为我国老龄人群健康长寿造福社会增加新的亮点。
纳米技术在中药和微量元素医学健康纺织品联合开发和应用:首先,纳米技术对物质的超细微粒化作用,纳米级粒子将使药中的细胞壁破损,将所有药效及元素释放出来,其粒径0.1-1um完全可以经皮肤(汗孔、毛孔粒径2um)、血液细胞粒径(6-9um)进入体内,提高了中药在体内的生物利用度和吸收率,增加疗效。而中药中的一些宏、微量元素,自然界天会给临床治疗带来突破性和意想不到的效果。随着人类高科技日新月异的高速发展,各式各样的高科技产品、家用电器走入人们的生活,提高了人们的工作效率,改变了人们的生活习惯,但也给人们带来了伤害。早在1998年世界卫生组织就提出:电磁波辐射污染已经成为继污水、空气、废气污染及噪声污染之后的第四大污染,是世界公认的“隐形杀手”。已被联合国人类环境会议列为必须控制的污染,用电磁波屏蔽材料、金属纤维和金属涂层纤维进行电磁波屏蔽,如氧化铁纳米粒子、铁氧化体纳米粒子、Fe2O3纳米粒子与硬脂酸复合LB膜等物质。
利用磁性Fe2O3、Fe3O4纳米微粒表面包敷麦饭石这种多孔穴,强力吸附有害物质不断释放微量元素的特性,或用这此磁性纳米粒,表面涂覆高分子材料后与蛋白质结合作为药物载体经皮肤渗透吸收到人体内,在外磁场的作用下、通过纳米磁性粒子的磁性导向性,使其中药及元素分子向病变部位移动,达到靶向定向治疗的目的。
药物制剂的给药途径与方法对药物使用至关重要,口服给药受到两种有关效应的影响,即胃肠道上皮细胞中酶系的将解,代谢和肝中各酶系的生物代谢。许多药物很大一部分因有关效应而代谢失效。如多肽、蛋白类药P-受体阻滞剂等,为了获得较好的治疗效果,通常不得不口服给药改为注射等。由于通过注射途径的非靶向药物可均匀的分布全身循环,在到达病变部位之前,通过体内的各种生物化学反应、各种酶、蛋白质的结合,排除代谢、分解等仅有少量的药物能达到病变部位。磁性靶向定向性给药的目的就是提高靶区的药物浓度、药物的利用吸收率和疗效。降低药物的副作用,通过制备含磁性物质(Fe2O3、Fe3O4)载药纳米粒、在外磁场的作用下,进行体外磁性导航,使其有效药效成分和元素分子移向脑部的额、颞、海马、基底节等病变部位,达到靶向定向治疗的目的。
将远红外辐射性物质中的金属氧化物MgO、ZnO、TiO2、SiO2、Fe2O3等和碳化物ZrC、MoC以及一种天然的能产生空气负离子的主要材料电气石。将这些远红外辐射物质及电气石粉末破碎至粒径为数微米乃至1um以下。一般来说粒径越小,纤维保湿性能越好,越优质。电气石超微粉碎后,在一定外部能量波动状态下(如体温、阳光、压力、磨擦、甚至是非常微小的作用下),即能引起负离子晶体之间高达1.0×106ev静电电势差,从而形成电场.高电压使电场中的空气电离被击中的电子通过电气石结晶微细粉末两端,所具有的永久正、负极,与普通的水、空气中的水分子或皮肤表面的水分子接触后就能产生瞬时放电电离效应.将水分电解为H+和OH-。H+与电气石释放出的电子结合而被中和成H原子,而OH-与其他水分子结合,可持续生成羟基负离子(H3O2 -)。经过这一过程的水,无论是碱性水还是酸性水,都会呈有益人体的弱碱性,还有其他的负离子材料,如天然矿石中蛋白石为含水非晶质水,都会呈有益人体的弱碱性,还有其他的负离子材料,如天然矿石中蛋白石为含水非晶质或胶质的活性SiO2以及少量的Fe2O3、Al2O3等,奇冰石为硅酸盐和铝、铁的金属氧化物构成的无机多孔物质。麦饭石以及海底的矿物,如珊瑚化石、海底沉积物、海藻炭等。这些物质主要是硅酸盐多孔物质,具有永久的自发电极,受到外界微小变化时,即能使周围空气电离,产生负离子:这种空气负离子的保健作用已被众多研究者所验证,是被人们广泛地称之为“长寿素”或“空气维生素”。当人们通过呼吸将空气中的负离子送进肺泡时,能刺激神经系统产生良好效应。经血液循环把所带电荷送到全身组织细胞中,能改善心肌功能,增强心肌营养和细胞代谢,提高肌体免疫力,增强肌体抵抗力,强身健体。益寿,人体吸入一定浓度的空气负离子,能调节人体神经系统功能。促进血液循环,使人精神旺盛、精力充沛、健康长寿。如果吸入相当量的空气负离子,还能驱除哮喘、高血压高血糖、高血粘度、神经衰弱、肺气肿、冠心病病等多种疾病。
本发明技术实施方案:
以有效防治脑猝中痴呆病的中药配方,临床经验方:经中药纳米技术后与磁性Fe2O3、Fe3O4及麦饭石和具有远红外辐射性物质中,使用最多的金属氧化物Al2O3、MgO、TiO2、SiO2、MnO2等及碳和物B4C、TiC、ZrC。以及能产生空气中负离子的主要材料电气石(奇冰石)或珊瑚化石、海藻炭等物质经纳米粉碎技术破碎至粒径为0.1-1um,最多不超过5um。由这些多种物质构成的多种化合物混合均匀后,将其在高温烧结成复合陶瓷,然后再经超声粉碎成纳米微粒细粉,然后按健康纤维纺织织物制造技术方法:(1)将陶瓷微粉粘合剂和助剂按一定比例配制成后整理剂,即是采用涂层整理方法,然后对织物进行涂层和浸轧,使后整理剂均匀地涂覆在纤维或织物上。经干燥、热处理使具有多种化合物质的混合陶瓷细纳米粉粒均匀地附着于织物的纱线之间,以及纱线的纤维之间;(2)将这些混合陶瓷纳米粉末直接加到聚丙烯晴纶、锦纶纺丝液中;也可把纳米陶瓷粉末分散到有机溶液中,再加到聚丙烯晴纶、锦纶等纺丝液中,还可以把这些纳米微粉末分散到含有芦荟纤维素衍生物的有机溶液中,再加聚丙烯晴纶、锦纶纺丝液中制成的织物。这种织物既具有防治脑猝中和脑痴呆的中药有效活性成分,天然绿色的宏、微量元素以及再添加经食用灵芝菌培养转化的有机硒和有机锗,就可以全面补充、调节、拮抗人体内元素平衡,还有远红外线发射能力的保健功能,以这些材料制成的织物防治帽。长期戴在头部使头部血液循环流速明显加快,人体头部皮肤几乎可以全部吸收织物防治帽发出的远红外线,并将其转换成热量向人体头部脑组织内部传播,使其组织内部温度升高。热能促进血管扩张,使硬化、阻塞或狭窄的血管的血流通畅和加速,使局部血管循环和微循环得到改善,提高了细胞的再生能力和肌体的免疫力。
由铁氧体的复合混合物组成的织物制得的防治帽具有Fe2O3、Fe3O4等金属磁铁微粉系列以及其功能的纳米材料系列,所以使得这种防治帽具有电磁波屏蔽性能,加至麦饭石、芦荟纤维等混纺而形成的纤维织物帽,具有多孔性、多元素、多功能性、多药效性的综合防治帽。当含纳米级TiO2、ZnO、SIO2等织物防治帽在阳光或在紫外线照射时,纳米级二氧化钛和氧化锌,能在水和空气存在的体系中自行分解出自由移动的电子(e-),同时留下带正电的空穴(H+),其反应如下:TiO2/ZnO+hu→e-+H+
e-+O2→·O2 -(空气中的氧被还原)
H++H2O→·OH+H+(吸附的水氧化)
由于·OH与·O2 -自由基非常活泼,能与包括细菌及其分泌毒素在内的有机物发生反应,从而将细菌和毒素杀灭和消除。
由于防治帽中含有电气石超细微纳米粉粒,所以在一定的外部能量波动状态下(如体温、阳光、磨擦力、甚至是非常微小的作用下),即会产生空气中的负离子。
这种含有电气石纳米粉末的防治帽在使用过程中,人体头部中的水分子与周围空气中的分子发生微弱的电解作用,产生羟基负离子,能调节你头部、面孔四周的空气质量,并与空气中带正电荷的有害混合物中和沉淀落入地下,使有害的物质得以清除,不断产生对人体有益的空气负离子。人体吸入空气中的负离子,即就是吸收空气中的维生素、长寿素、营养素及微量元素,使你的营养均衡、元素平衡、酸碱平衡。
下面结合实施例子对本发明进一步说明:
实施例一:中药方剂部分
(一)脑猝中
(1)中经络:钩藤、菊花、夏枯草、珍珠母各30g,各占18.2%;
怀牛膝20g,占12.1%;丹皮15g占9%;
赤芍10g,占6%。
主治因中经络的脑猝中者:
①肝阳上亢、风炎上扰证用此方
主治:半身不遂、偏身麻木、舌强言寡或不语、口舌歪斜、眩晕头痛、面红而赤、心烦易怒、尿赤便干、舌质红、红绛、舌苔黄,脉弦有力,用上方去平肝泻大通络。
②黄芪150g,占31.6%;赤芍100g,占21.1%;
川芎25g,占5.3%。
③钩藤、桑寄生各150g,占20.6%;
生地、白芍各100g,占13.8%;
玄参、女贞子、丹参各75g,各占10.3%。
(2)中脏腑
①天麻、莆芩、山栀、天竺黄、川牛膝各50g,各占8.5%;
钩藤100g,占16.9%;生决明150g,占25.4%;
丹皮60g,占10.1%;生大黄30g,占5%。
②制半夏、枳实、菖蒲、竹茹、远志各50g,各占11.1%;
陈皮、胆南星各30g,各占7.1%;
茯苓100g,占23.8%;生姜10g,占2.4%。
(二)脑猝中后遗症
(1)半身不遂
黄芪、鸡血藤150g,各占19.2%;
川芎、当归、地龙、桃仁、穿山甲、丝瓜络各50g,占6.4%;
赤芍60g,占7.4%;威灵仙75g,占9.6%;
红花30g,占3.8%;水蛭粉15g,占1.9%。
(2)语言不利
石斛、丹参各75g,各占9.7%;
山萸肉、何首乌、菖蒲、菊花各50g,各占6.5%;
五味子、远志各30g,各占3.9%;
熟地、肉苁蓉各150g,各占19.5%;
枸杞子60g,占7.8%。
(3)癫痫、中风后引起
天麻、僵蚕各75g,各占13.6%;
菖蒲、半夏、腥南、茯神、玳瑁各50g,各占9.1%;
郁金60g,占10.9%;全蝎、远志、猪牙皂各30g,占5.5%。
(4)反复中风引起的痴呆
半夏、枳实、菖蒲各50g,各占11.5%;
胆南星、橘红、竹茹、川芎各30g,各占6.9%;
茯苓、丹参75g,各占17.2%;
水蛭粉15g,占3.7%。
(三)老年痴呆病
(1)熟地30g,占14.2%;
肉苁蓉、何首乌、怀牛膝、茯苓各15g,各占0.7%;
枸杞子、山萸肉、巴戟天、紫河车、鹿角胶(烊化)、龟板胶(烊化)、杜仲、赭实子、当归、山药、菖蒲各10g,各占0.05%;
远志、五味子各6g,各占0.03%。
适应症:肝肾亏虚、脑髓不充:
表现:神情呆滞、动作迟缓、步覆蹒跚、寡言少语、健忘或呆傻、不识家门,重者饮食起居需人照顾、二便失禁、头晕目眩、腰膝酸软、舌质暗红少苔、脉细弦、两天独弱。
治宜滋补肝肾、填髓益智
肢体强痉加白芍、木瓜、嶄蛇、僵蚕5-10g,方用还冉加减。
(2)茯神、酸枣仁各75g,各占8.5%;
生晒参、灸甘草、半夏、陈皮、菖蒲、神曲各50g,占5.7%;
制附子30g,占3.4%;
心气不足加麦冬、五味子、丹参各50g,淤血内阻加桃仁、川芎、郁金、红花、水蛭各50g,占5.7%。
适应症:脾虚疾浊、禁塞清窍
临床证见:终日不言不语、不饮不食、表情淡漠、无主动性或喃喃自语、失语失谈、动作刻板、终日卧床不动、面色苍白或苍白不泽、气短乏力;舌体胖、舌质淡或淡暗、苔白腻、脉细滑。
治宜益气健脾、化疾开窍
方用泻心汤加碱。
(3)太子参250g,占28.3%;熟地100g,占18.9%;
天冬、川芎、制南星各50g,各占9.4%;远志30g,占5.7%。
实施例二:微量元素远红外电磁波负离子纤维部分
纳米硒、锗、纳米粉 2 %
Fe2O3、Al2O3、ZnO 3 %
TiO2、SiO2、MnO2 3 %
B4C、SiC、ZrC 3 %
麦饭石纤维纳米粉 6 %
电气石纳米晶体粉末 8 %
针对某种疾病的中药配方 15 %
丙烯晴纶或锦纶纤维 20 %
粘胶纤维 20 %
芦荟纤维 20 %
总计 100 %
实施例三:
取灵磁石一块制成厚0.5cm,长2cm,宽2cm的正方形灵磁石12-20块。用棉白纱布缝制成若干个与2×2cm的小方格,置灵磁石于棉白纱布内制成与病人头部大小的小垫帽,灵磁石正好置于病者脑部病变部位,一般为下丘脑后部、丘脑及中线附近组织、颞叶部位及两侧海马、基底节等病变部位。每天使用4-6个小时,连用半个月,连续使用3次为一个疗程,可连续使用3个疗程。目的达到靶向,磁性定向性治疗的目的。
Claims (5)
1.纳米硒、锗元素中药脑猝中痴呆病防治帽,其特征是:制作防治帽的织物内含有纳米硒、锗及具有远红外辐射物质,同时又具有电磁波屏蔽作用,和抗菌抗病毒作用的纳米TiO2、ZnO、Fe2O3、Al2O3等金属氧化物、碳化物和中药方剂及麦饭石纤维、电气石、晴纶、锦纶、粘胶纤维等组成。
2.根据权利要求书1所述,纳米硒、锗元素中药脑猝中痴呆病防治帽,其特征是他们所有物质的混合物必须经现代超声波纳米粉碎加工技术其中心粒径0.1~10um。
3.根据权利要求书1、2所述,纳米硒、锗元素中药脑猝中痴呆病防治帽,其特征是根据不同的病症选用不同的中药配方,按比例添加到纤维织物中。
(一)脑猝中
(1)中经络方
①钩藤、菊花、夏枯草、珍珠母各10-50g,各占15-22%;
怀牛膝10-30g,占8-15%;丹皮10-20g占;
赤芍5-15g,占3-10%。
②黄芪100-200g,占25-36%;赤芍50-150g,占15-21%;
桃仁、红花、归尾、地龙20-80g,各占5-11%;
川芎20-30g,占3-7%。
③钩藤、桑寄生各100-200g,占15-26%;
生地、白芍各50-150g,占8-22%;
玄参、女贞子、丹参各50-90g,各占5-11%。
(2)中脏腑方
①天麻、莆芩、山栀、天竺黄、川牛膝各30-80g,各占4-12%;
钩藤50-150g,占11-22%;生决明100-200g,占20-31%;
丹皮30-100g,占5-11%;生大黄15-50g,占1-10%。
②制半夏、枳实、菖蒲、竹茹、远志各20-80g,各占5-12%;
陈皮、胆南星各10-50g,各占5-10%;
茯苓50-150g,占18-29%;生姜5-15g,占1-4%。
(二)脑猝中后遗症
(1)半身不遂
黄芪、鸡血藤100-200g,各占15-25%;
川芎、当归、地龙、桃仁、穿山甲、丝瓜络各30-80g,占1-11%;
赤芍40-80g,占3-12%;威灵仙60-80g,占5-15%;
红花10-50g,占1-5%;水蛭粉10-20g,占0.5-3%。
(2)语言不利
石斛、丹参各50-90g,各占5-15%;
山萸肉、何首乌、菖蒲、菊花各20-80g,各占2-11%;
五味子、远志各10-50g,各占1-5%;
熟地、肉苁蓉各100-200g,各占15-26%;
枸杞子40-120g,占5-12%。
(3)癫痫、中风后引起
天麻、僵蚕各50-90g,各占8-19%;
菖蒲、半夏、腥南、茯神、玳瑁各20-70g,各占5-15%;
郁金40-80g,占5-15%;全蝎、远志、猪牙皂各10-40g,占1-11%。
(4)反复中风引起的痴呆
半夏、枳实、菖蒲各30-70g,各占6-16%;
胆南星、橘红、竹茹、川芎各10-50g,各占2-11%;
茯苓、丹参50-100g,各占15-22%;
水蛭粉10-20g,占1-5%。
(三)痴呆病
(1)熟地20-40g,占10-20%;
肉苁蓉、何首乌、怀牛膝、茯苓各10-20g,各占0.2-1.2%;
枸杞子、山萸肉、巴戟天、紫河车、鹿角胶(烊化)、龟板胶(烊化)、杜仲、赭实子、当归、山药、菖蒲各5-15g,各占0.01-0.1%;
远志、五味子各1-11g,各占0.01-0.05%。
(2)茯神、酸枣仁各50-100g,各占3-13%;
生晒参、灸甘草、半夏、陈皮、菖蒲、神曲各40-60g,占2-9%;
制附子10-50g,占1-5%;
心气不足加麦冬、五味子、丹参,淤血内阻加桃仁、川芎、郁金、红花、水蛭各30-70g,占2-9%。
(3)太子参120-170g,占23-30%;熟地80-120g,占13-23%;
天冬、川芎、制南星各30-80g,各占5-15%;远志20-40g,占1-10%。
4.根据权利要求书1、2、3所述,纳米硒、锗元素中药脑猝中痴呆病防治帽,其特征是:还需添加下列微量元素远红外电磁波负离子纤维部分:
纳米硒、锗、纳米粉 1~3 %
Fe2O3、Al2O3、ZnO 2~5 %
TiO2、SiO2、MnO2 2~5 %
B4C、SiC、ZrC 2~5 %
麦饭石纤维纳米粉 4~8 %
电气石纳米晶体粉末 6~10 %
针对某种疾病的中药配方 10~20 %
丙烯晴纶或锦纶纤维 1~30 %
粘胶纤维 15~30 %
芦荟纤维 15~30 %
总计 100 %
5.根据权利要求书1、2、3、4所述,纳米硒、锗元素中药脑猝中痴呆病防治帽,其特征是:还需配备灵磁石的内垫帽,灵磁石厚0.1-1cm,长×宽0.5-3.5cm,共4-20块,用棉纱布做成的小方格内垫灵磁石的内垫帽。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910233888A CN101703824A (zh) | 2009-10-23 | 2009-10-23 | 纳米硒、锗元素中药脑猝中痴呆病防治帽 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910233888A CN101703824A (zh) | 2009-10-23 | 2009-10-23 | 纳米硒、锗元素中药脑猝中痴呆病防治帽 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101703824A true CN101703824A (zh) | 2010-05-12 |
Family
ID=42374118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910233888A Pending CN101703824A (zh) | 2009-10-23 | 2009-10-23 | 纳米硒、锗元素中药脑猝中痴呆病防治帽 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101703824A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104988791A (zh) * | 2015-06-25 | 2015-10-21 | 广东义晟实业有限公司 | 一种抗病毒添加剂及添加该添加剂的胶水和uv漆 |
| CN107740199A (zh) * | 2017-08-23 | 2018-02-27 | 深睡(天津)科技发展有限公司 | 一种托玛琳抗菌粘胶纤维及其高效制备方法 |
| CN115591114A (zh) * | 2016-12-21 | 2023-01-13 | 纳米生物技术公司(Fr) | 用于提高脑性能或用于治疗应激的纳米粒子 |
| CN117756187A (zh) * | 2023-12-25 | 2024-03-26 | 江南大学 | 一种手性Se/Fe2O3纳米材料及其制备方法与应用 |
-
2009
- 2009-10-23 CN CN200910233888A patent/CN101703824A/zh active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104988791A (zh) * | 2015-06-25 | 2015-10-21 | 广东义晟实业有限公司 | 一种抗病毒添加剂及添加该添加剂的胶水和uv漆 |
| CN115591114A (zh) * | 2016-12-21 | 2023-01-13 | 纳米生物技术公司(Fr) | 用于提高脑性能或用于治疗应激的纳米粒子 |
| CN107740199A (zh) * | 2017-08-23 | 2018-02-27 | 深睡(天津)科技发展有限公司 | 一种托玛琳抗菌粘胶纤维及其高效制备方法 |
| CN117756187A (zh) * | 2023-12-25 | 2024-03-26 | 江南大学 | 一种手性Se/Fe2O3纳米材料及其制备方法与应用 |
| CN117756187B (zh) * | 2023-12-25 | 2025-07-11 | 江南大学 | 一种手性Se/Fe2O3纳米材料及其制备方法与应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100356974C (zh) | 一种保健酒及其制备方法 | |
| CN102926012A (zh) | 纳米硒锗负离子远红外防紫外线防蚊拒水磁疗旅游垫褥帐蓬 | |
| CN101953513A (zh) | 防治脑痴呆的纳米元素负离子远红外织物内衣 | |
| CN101953516A (zh) | 现代文明病的纳米元素负离子远红外抗菌织物内衣 | |
| CN101703824A (zh) | 纳米硒、锗元素中药脑猝中痴呆病防治帽 | |
| CN102697830A (zh) | 一种防治经期疾病的药物组合物及其制备方法和应用 | |
| CN102302224A (zh) | 纳米银负离子远红外防治风湿性关节炎元素织物内衣 | |
| CN101703668A (zh) | 防治盆腔炎的纳米银远红外抗菌芦荟纤维织物脐阴带 | |
| CN101129609A (zh) | 明目菊花散 | |
| CN102091237A (zh) | 纳米磁性负离子远红外功效性衣冠疗法用品 | |
| CN105708254B (zh) | 功效性磁疗睡袋 | |
| CN101366903B (zh) | 一种治疗更年期综合症的中药组合物 | |
| CN106222792A (zh) | 富硒锗防癌克螨元素织物强身服 | |
| CN107595473B (zh) | 一种智能纳米石墨烯抗菌理疗保健眼罩 | |
| CN101836920A (zh) | 一种远红外线活氧负离子卫生巾及保健垫 | |
| CN101612347A (zh) | 一种治疗月经不调的保健药酒 | |
| CN103239625B (zh) | 一种治疗面神经麻痹症的中药制剂 | |
| CN104606636B (zh) | 一种治疗抑郁症的中药组合物及其制备方法 | |
| CN201216756Y (zh) | 男士负离子卫生护垫 | |
| CN101756400A (zh) | 麦饭石粘胶纤维纳米元素中药功能性织物领带 | |
| CN102197893A (zh) | 纳米银负离子远红外防治肾炎的纤维织物宽腰带 | |
| CN103212050A (zh) | 神阙粉 | |
| CN102038619B (zh) | 一种泡澡颗粒及其制备方法 | |
| CN106087086A (zh) | 交警夏用户外执勤防护服 | |
| CN108514634A (zh) | 肚脐贴膏 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20100512 |